Answers are grounded in this paper and cite their sources.
Several Janus kinase (JAK) inhibitors have been developed in recent years. These agents are widely applicable in clinical practice as an alternative treatment for immune-mediated diseases. While the safety and efficacy profile of these drugs has been evaluated in several randomized clinical trials and studies, very few authors have assessed safety and effectiveness under the real-world conditions of daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Huaranga et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: